Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Lung Neoplasms 3Primary Myelofibrosis 1Pancreatic Neoplasms 1Myelodysplastic Syndromes 1Metastatic Pancreatic Ductal Adenocarcinoma 1Leukemia, Myelomonocytic, Chronic 1Gastrointestinal Neoplasms 1Clonal Cytopenia of Undetermined Significance 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

enasidenib 1canakinumab 1X-Rays 1Specimen Handling 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Clonal Cytopenia of Undetermined Significance × canakinumab × Clear all
NCT05641831 2026-01-02

Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
110 enrolled
Classical hematology

Clonal Cytopenia of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡